Literature DB >> 8047818

The role of acid inhibition in the treatment of Helicobacter pylori infection.

A T Axon1.   

Abstract

The recognition that Helicobacter pylori is a causal factor in the development of most peptic ulcers (and may play a role in the pathogenesis of gastric cancer) has provided an impetus to the search for a suitable regimen that will eradicate the organism. Combinations of antibiotics with bismuth (triple therapy) eradicate the organism in around 90% of cases, but the regimens are complicated, and poor compliance and significant side effects are frequently seen. The observation that omeprazole in combination with a single antibiotic provides eradication rates of over 80% is an important advance, as this combination is a simple regimen and is well tolerated. In this article, the role of omeprazole in eradication therapy is discussed, the published data are reviewed and hypotheses relating to the mode of action of omeprazole are presented. Although the optimum therapy has yet to be identified, acceptable results should be obtained by using omeprazole, 40 mg twice daily, plus amoxycillin, 500 mg four times daily, for 2 weeks.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047818

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  15 in total

1.  H pylori infection.

Authors:  P S Phull; M R Jacyna
Journal:  Br J Gen Pract       Date:  1996-01       Impact factor: 5.386

2.  Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.

Authors:  G Bianchi Porro; F Parente; V Imbesi; F Montrone; I Caruso
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

3.  How should we decide on the best regimen for eradicating Helicobacter pylori?

Authors:  V Savarino; S Vigneri
Journal:  BMJ       Date:  1995-09-02

4.  High seroprevalence of IgG against Helicobacter pylori among endoscopists in Taiwan.

Authors:  Y C Su; W M Wang; L T Chen; W Chiang; C Y Chen; S N Lu; C M Jan
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

5.  Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.

Authors:  P Moayyedi; D M Chalmers; A T Axon
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

Review 6.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 7.  Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia.

Authors:  B C Delaney
Journal:  Br J Gen Pract       Date:  1995-09       Impact factor: 5.386

8.  Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori.

Authors:  N Nagahara; Y Akiyama; M Nakao; M Tada; M Kitano; Y Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 9.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

10.  Dual drug delivery system for targeting H. pylori in the stomach: preparation and in vitro characterization of amoxicillin-loaded Carbopol® nanospheres.

Authors:  Sree Harsha
Journal:  Int J Nanomedicine       Date:  2012-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.